Oculis Holding Raises $100 Million in Oversubscribed Share Offering

Oculis Holding AG has priced an underwritten offering of 5 million ordinary shares at $20.00 per share, aiming to raise $100 million in gross proceeds, with the offering expected to close around February 18, 2025. The oversubscribed offering will primarily fund the clinical development of Oculis' neuroprotective candidate, Privosegtor (OCS-05), as well as support working capital and general corporate purposes. This funding move is part of Oculis' strategy to enhance its operational capabilities in the biopharmaceutical sector, particularly in treating ophthalmic and neuro-ophthalmic diseases. The total number of registered shares will increase to 53,943,700 following this offering. BofA Securities and Leerink Partners are acting as joint bookrunners for the offering, with Pareto Securities serving as the lead manager. Oculis is headquartered in Switzerland and operates globally, focusing on unmet medical needs in eye health.